Antidepressant Response of DMT Masked With Propofol

Ki vehet részt

• Participants must meet DSM-5 criteria for MDD of at least moderate severity (MADRS≥20)
• Participants either currently do not use antidepressants or are treated with a stable dose for at least 4 weeks prior to randomization
• Age ≥ 21 years old
• Sufficient understanding of the German language
• Able to understand the study procedures and risks and willing to adhere to the protocol and sign the consent form
• Willing not to drive or operate heavy machinery on the treatment day
• Willing to refrain from more than 7 standard alcoholic drinks a week, more than 10 cigarettes a day, more than 2 cups of coffee a day, and any illicit substances during study participation
• Willing to use effective contraceptive measures throughout study participation

Ki nem vehet részt

• Patients who are treated with neuroleptics or known antagonists of 5-HT2 receptors or monoamine oxidase inhibitors (MAOI) and are not able/willing to pause
• Past or present bipolar or psychotic disorder, including depressive disorder with psychotic features
• First-degree relative with a psychotic or bipolar disorder
• Psychiatric condition judged to be incompatible with establishment of rapport with study team members and/or safe exposure to DMT, e.g. diagnosed or suspected borderline personality disorder
• Current post-traumatic stress disorder or acute stress reaction due to a traumatic event
• Current or recent history of significant suicide ideation or suicide behavior within the past 6 months
• Current severe substance use disorder other than nicotine
• Significant prodromal psychotic symptoms (Prodromal Questionnaire-16 symptoms ≥ 6)
• Post-partum depression
• Pregnant or breastfeeding women
• Planned ketamine, other psychedelic, or electroconvulsive treatment or any such treatment within the past 3 months
• Any lifetime use of DMT, use of any other psychedelics within last 3 month or lifetime use of any other psychedelics more than 15 times
• Increased risk for adverse reactions to propofol or soja products
• Increased risk for aspiration
• Increased risk for difficult mask ventilation